Trust Investment Advisors Acquires New Stake in Insulet Co. (NASDAQ:PODD)

Trust Investment Advisors bought a new stake in shares of Insulet Co. (NASDAQ:PODD) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 820 shares of the medical instruments supplier’s stock, valued at approximately $214,000.

Other institutional investors also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new stake in shares of Insulet during the fourth quarter worth about $69,433,000. Alecta Tjanstepension Omsesidigt purchased a new position in Insulet in the 4th quarter valued at approximately $53,184,000. Proficio Capital Partners LLC purchased a new stake in shares of Insulet during the fourth quarter worth $28,422,000. Baillie Gifford & Co. boosted its holdings in Insulet by 3.5% in the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock valued at $614,998,000 after purchasing an additional 79,982 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec acquired a new position in Insulet during the 3rd quarter worth $16,342,000.

Insider Buying and Selling

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.47% of the company’s stock.

Insulet Stock Performance

Shares of PODD opened at $272.71 on Wednesday. The company’s 50 day simple moving average is $272.27 and its 200-day simple moving average is $258.19. The firm has a market cap of $19.15 billion, a PE ratio of 47.10, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. As a group, equities analysts predict that Insulet Co. will post 3.92 EPS for the current year.

Wall Street Analyst Weigh In

PODD has been the topic of a number of analyst reports. Stifel Nicolaus increased their price target on Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Wells Fargo & Company raised their target price on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group boosted their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. TD Cowen raised their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Finally, StockNews.com downgraded shares of Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.